Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Flyte, the regional air mobility subsidiary of Catheter Precision (NYSE American:VTAK), has joined the Vaunt operator network, a membership-based private aviation platform owned by Volato Group (NYSE American:SOAR).
The partnership gives Flyte’s Cirrus Vision Jet fleet access to Vaunt’s fast-growing member base, creating opportunities to monetize repositioning flights, increase aircraft utilization, and support revenue growth. Vaunt recently reported annual recurring revenue of $3.6 million, up 162% year-over-year. Eligible Vaunt members may receive a $1,000 credit toward qualifying Flyte charters booked directly with Flyte.
Flyte (NASDAQ: VTAK), a regional air mobility company, outlined its activation strategy for the 2026 FIFA World Cup. The plan targets high-value, short-haul travel and brand exposure as millions of visitors move among host cities in the US, Canada, and Mexico.
Flyte is focusing on dense Northeast corridor routes linking New York (HPN/TEB) with Boston (BED), Philadelphia (PNE/TTN), and Washington, D.C. (IAD). Its model emphasizes rapid aircraft repositioning, high-frequency service, same-day flexible scheduling, and group and premium traveler bookings to participate in continuous tournament-related travel demand.
Flyte (NYSE: VTAK), the regional air mobility subsidiary of Catheter Precision, announced a strategic investment in Volato Group (NYSE: SOAR). Flyte acquired about 2.9 million SOAR shares, becoming Volato's largest shareholder with an estimated 7.5% ownership, supporting potential collaboration and growth for both companies.
Volato Group (NYSE American: SOAR) signed a definitive agreement for a $2.2 million strategic investment in restricted common stock, led by Catheter Precision and other institutional investors. The capital is intended to strengthen the balance sheet and support a shift toward AI infrastructure and technology transactions.
The company terminated its prior M2i Global deal and is now evaluating non-binding AI-related letters of intent, while leveraging its existing AI software platform Parslee and the Volato AI initiative. Closing remains subject to NYSE American listing approval and other customary conditions.
Flyte, a subsidiary of Catheter Precision (NASDAQ:VTAK), is deploying its Cirrus Vision Jet fleet across the Northeast for the Belmont Stakes at Saratoga Race Course on June 6, 2026. The high-frequency, short-haul program targets dense, time-sensitive Triple Crown travel demand.
Key routes include NYC (HPN/TEB), East Hampton, and Boston (BED) to Saratoga Springs, with same-day inbound and outbound rotations, group and shared-cabin options, and operations flown by FAA Part 135 carrier Ponderosa Air.
Catheter Precision (NYSE:VTAK) reported Q1 2026 revenue of $432,000, up 200% year-over-year from $143,000, driven by its medical device business and newly acquired Flyte aviation platform.
Net loss improved to $1.7 million from $4.0 million as Flyte rapidly scaled and medical devices expanded globally.
Flyte, a regional air mobility subsidiary of VTAK (NYSE American: VTAK), is deploying aircraft across the Northeast to serve peak travel demand for the Preakness Stakes on Saturday, May 16. Centered on Baltimore/Washington International (BWI), the high-frequency short-haul program targets premium, time-sensitive travelers.
Core routes from New York, Boston, Washington, D.C., and Philadelphia, plus expansion routes from Charlotte and Raleigh-Durham, are structured for dense, rapid-cycle schedules aimed at maximizing aircraft utilization and capturing event-driven revenue opportunities.
Flyte (NYSE American: VTAK) is increasing flight capacity and launching a targeted hiring initiative after Spirit Airlines ceased operations on May 2, 2026. Flyte is accelerating its planned Vision Jet fleet expansion, broadening regional route coverage, and opening a structured onboarding pipeline for impacted pilots and aviation professionals.
The company framed these steps as part of its existing growth plan and says they aim to support utilization and service availability amid reduced commercial capacity and tighter fares on certain domestic corridors.
Catheter Precision (NYSE:VTAK) will attend the 47th Heart Rhythm Society meeting in Chicago, April 24–27, 2026, featuring the VIVO system in a poster (April 24) and a core-session presentation (April 25). Two new peer‑reviewed papers for LockeT (139 patients) and VIVO (31 patients, 48 VTs) are published online.
The announcements emphasize feasibility data for intracardiac VT localization, workflow benefits for VT ablation, and LockeT venous‑closure outcomes including high procedural success and low complication rates.
Catheter Precision (NYSE American: VTAK) received a Notice of Allowance from the USPTO on April 21, 2026, for key claims covering its LockeT surgical vessel closing pressure device.
The allowed claims protect both the device architecture and method of use, reinforcing the company’s intellectual property position, creating barriers to entry, and supporting its IP-driven commercialization and growth strategy.